Postmenopausal hormone therapy is not associated with risk of all-cause dementia and alzheimer's disease

Epidemiologic Reviews

Volumn 36, Issue 1, 2014, Pages 83-103

  O'Brien, Jacqueline ^a   Jackson, John W ^a   Grodstein, Francine ^a   Blacker, Deborah ^a   Weuve, Jennifer ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer disease; clinical trial; cognition; cohort studies; dementia; estrogen replacement therapy; hormone replacement therapy; systematic review

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; HORMONAL THERAPY; HUMAN; MENARCHE; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COHORT STUDIES; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; HORMONE REPLACEMENT THERAPY; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; CAUSALITY; DEMENTIA; DRUG ADMINISTRATION SCHEDULE; HEALTH STATUS INDICATORS; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE;

EID: 84891519572     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxt008     Document Type: Article

References (76)

1. Krieger N, Lowy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health. 2005; 59(9):740-748.
2. Henderson VW. Action of estrogens in the aging brain: dementia and cognitive aging. Biochim Biophys Acta. 2010;1800(10):1077-1083.
3. Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev. 2010;31(2):224-253.
4. Brinton RD, Chen S, Montoya M, et al the estrogen replacement therapy of theWomen's Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease. Maturitas. 2000;34(2):S35-S52.
5. Tanapat P, Hastings NB, Reeves AJ, et al. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat. J Neurosci. 1999; 19(14):5792-5801.
6. Pike CJ, Carroll JC, Rosario ER, et al. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol. 2009;30(2):239-258.
7. Georgiadou P, Sbarouni E. Effect of hormone replacement therapy on inflammatory biomarkers. Adv Clin Chem. 2009;47:59-93.
8. Nelson HD,Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2012;157(2): 104-113.
9. Coker LH, Espeland MA, Rapp SR, et al. Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol. 2010;118(4-5):304-310.
10. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: theWomen's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651-2662.
11. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women:Women's Health Initiative Memory Study. JAMA. 2004;291(24): 2947-2958.
12. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women:Women's Health Initiative Memory Study. JAMA. 2004;291(24):2959-2968.
13. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2663-2672.
14. Moyer VA, on behalf of the USPSTF. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(1):47-54.
15. Gleason CE, Dowling NM, Friedman E, et al. Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy? Menopause. 2012;19(5):524-533.
16. Matthews KA, Kuller LH,Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143(10):971-978.
17. Brinton RD the healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008;31(10):529-537.
18. Seshadri S,Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease the impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49(6): 1498-1504.
19. Hebert LE,Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 Census. Neurology. 2013;80(19):1778-1783.
20. Barrett-Connor E, Laughlin GA. Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials. Semin Reprod Med. 2009;27(3):275-282.
21. Dye RV, Miller KJ, Singer EJ, et al. Hormone replacement therapy and risk for neurodegenerative diseases. Int J Alzheimer Dis. 2012;2012:258-454.
22. Lethaby A, Hogervorst E, Richards M, et al. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD003122.
23. Maki PM. A systematic review of clinical trials of hormone therapy on cognitive function: effects of age at initiation and progestin use. Ann N Y Acad Sci. 2005;1052: 182-197.
24. Marjoribanks J, Farquhar C, Roberts H, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7:CD004143.
25. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA.1998;279(9):688-695.
26. LeBlanc ES, Janowsky J, Chan BK, et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285(11): 1489-1499.
27. Hogervorst E,Williams J, Budge M, et al the nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a metaanalysis. Neuroscience. 2000;101(3):485-512.
28. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15): 2008-2012.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
31. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634.
32. Barnes LL,Wilson RS, Schneider JA, et al. Gender, cognitive decline, and risk of AD in older persons. Neurology. 2003; 60(11):1777-1781.
33. Brenner DE, KukullWA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140(3):262-267.
34. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48(6):1517-1521.
35. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5): 445-453.
36. Petitti DB, Crooks VC, Chiu V, et al. Incidence of dementia in long-term hormone users. Am J Epidemiol. 2008;167(6):692-700.
37. Roberts RO, Cha RH, Knopman DS, et al. Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings. Alzheimer Dis Assoc Disord. 2006;20(3):141-146.
38. Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology. 2009;73(21):1729-1737.
39. Ryan J, Carriere I, Scali J, et al. Life-time estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinology. 2009;34(2):287-298.
40. Seshadri S, Zornberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58(3):435-440.
41. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. 2012;79(18):1846-1852.
42. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348(9025):429-432.
43. Waring SC, RoccaWA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: a populationbased study. Neurology. 1999;52(5):965-970.
44. Whitmer RA, Quesenberry CP, Zhou J, et al. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol. 2011;69(1):163-169.
45. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA.;288(17): 2123-2129.
46. Boustani M, Peterson B, Hanson L, et al. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138(11):927-937.
47. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogenreplacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998;50(4): 996-1002.
48. Olichney JM, Hofstetter CR, Galasko D, et al. Death certificate reporting of dementia and mortality in an Alzheimer's disease research center cohort. J Am Geriatr Soc. 1995;43(8): 890-893.
49. Friedman-Koss D, Crespo CJ, Bellantoni MF, et al the relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994. Menopause. 2002;9(4):264-272.
50. Lawlor DA, Davey Smith G, Ebrahim S. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health. 2004;94(12): 2149-2154.
51. Persson I, Bergkvist L, Lindgren C, et al. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol. 1997;50(5):611-618.
52. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003;348(7):645-650.
53. Haskell SG, Bean-Mayberry B, Goulet JL, et al. Determinants of hormone therapy discontinuation among female veterans nationally. Mil Med. 2008;173(1):91-96.
54. Wei F, Miglioretti DL, Connelly MT, et al. Changes in women's use of hormones after theWomen's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr. 2005;(35):106-112.
55. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogenactivated protein kinase signaling. Proc Natl Acad Sci USA. 2003;100(18):10506-10511.
56. Hogervorst E, Yaffe K, Richards M, et al. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2009;(1):CD003799.
57. Henderson VW, Brinton RD. Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Prog Brain Res. 2010;182:77-96.
58. Henderson VW the neurology of menopause. Neurologist. 2006;12(3):149-159.
59. Lakey SL, Reed SD, LaCroix AZ, et al. Self-reported changes in providers' hormone therapy prescribing and counseling practices after theWomen's Health Initiative. J Womens Health. 2010;19(12):2175-2181.
60. Modena MG, Bursi F, Fantini G, et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med. 2002; 113(4):331-334.
61. Koyama A, O'Brien J,Weuve J, et al the role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Geront Ser A Biol Sci Med Sci. 2013; 68(4):433-440.
62. Steingold KA, Matt DW, DeZiegler D, et al. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab. 1991;73(2):275-280.
63. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-lowdose transdermal estradiol on cognition and health-related quality of life. Arch Neurol. 2006;63(7):945-950.
64. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53(3):605-619.
65. Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci. 2005;1052:57-74.
66. Tsagkas V, Turner S. Hormone therapy has many favorable effects in newly menopausal women: initial findings of the Kronos Early Estrogen Prevention Study (KEEPS). Phoenix, AZ: Kronos Longevity Research Institute; 2012. (http://www. keepstudy.org/news/pr-100312-a.cfm). (Accessed February 7, 2013).
67. Wilson RS, Leurgans SE, Boyle PA, et al. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol. 2011;68(3):351-356.
68. Low LF, Anstey KJ. Hormone replacement therapy and cognitive performance in postmenopausal women-a review by cognitive domain. Neurosci Biobehav Rev. 2006; 30(1):66-84.
69. Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging. 2012;33(7):1129-1137.
70. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology. 2001; 57(12):2210-2216.
71. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91(5): 1802-1810.
72. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab. 2009;94(11):4152-4161.
73. Guay MP, Dragomir A, Pilon D, et al. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Safety. 2007; 16(1):17-27.
74. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011;18(4):385-392.
75. Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of theWomen's Health Initiative. Menopause. 2012;19(6):616-621.
76. North American Menopause Society the 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19(3):257-271.